Big Pharma veteran Dr. Alexander (Sandy) Macrae has taken on the role of president and CEO of Californian biotech Sangamo Biosciences after the retirement of its former head Edward O. Lanphier, who will become the company’s chairman.
The company said that Lanphier has retired from his position as the company’s president and CEO effective today, and will become its new non-executive chair later this month. Its new leader Dr. Macrae, 53, comes with a long service history in the Big Pharma arena, previously being the global medical officer of Takeda from 2012 to March 2016. Dr. Macrae also held various positions at GlaxoSmithKline since 2004. He was educated in the U.K.
The company focuses on gene editing technology, with trials ongoing in HIV/AIDS and hemophilia A and B, and currently has a market cap of around $500 million.
In a SEC filing announcing the change, the company disclosed that Dr. Macrae will receive a base salary of $600,000 per year, while also being able to gain an annual cash bonus should the company hit its targets.
And that’s not all–Dr. Macrae will also be given $200,000 as a “sign-on bonus”–although that will need to be returned should he leave “without good reason” within the next year. He can also purchase up to 700,000 shares of common stock of the company.
The biotech has had mixed fortunes in recent months after Shire ended its 3-year gene editing pact, with each company hanging on to the programs best aligned to its goals.
The pair joined up in 2012 when Shire paid $13 million up front and promised undisclosed millions more to work with Sangamo on so-called ZFP therapeutics, lab-crafted proteins designed to interrupt DNA sequences and correct genetic defects.
But in fall of last year the two split up, with Shire handing back the rights to early-stage, ZFP-powered treatments for hemophilia A and B but keeping some Sangamo-discovered leads in Huntington’s disease and another undisclosed target.
The company’s $320 million deal with Biogen focused on hemoglobinopathies–such as sickle cell disease and beta-thalassemia–is however still on.
By Ben Adams
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.